Ziconotide: a clinical update and pharmacologic review

Bibliography

• Available from: http://www.washingtontimes.com/news/2013/jan/11/ny-mayor-bloomberg-limit-pain-medication-hospitals/
   Google Scholar
• Coffey RJ, Owens ML, Broste SK, Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 2009;111:881-91
   PubMed Web of Science ®Google Scholar
• Deer TR, Prager J, Levy R, Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15(5):436-64
   PubMed Web of Science ®Google Scholar
• Medtronic update: increased risk of motor stall and loss of or change in therapy with unapproved drug formulations. 2012. http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm333231.htm
   Google Scholar
• Dewilde S, Verdian L, MacLaine GDH. Cost effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin 2009;25(8):2007-19
   PubMed Web of Science ®Google Scholar
• Available from: http://navigatorprogram.com/
   Google Scholar
• Westenbroek RE, Hoslins L, Cattarall WA. Localization of Ca 2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 1998;18(16):6319-30
   PubMed Web of Science ®Google Scholar
• Kerr LM, Filloux F, Olivera BM, Autoradiographic localization of calcium challes with [125I] omega-conotoxin in rat brain. Eur J Pharmacol 1988;146:181-3
   PubMed Web of Science ®Google Scholar
• Schmidtko A, Lotsch J, Freynhagen R, Ziconotide for treatment of severe chronic pain. Lancet 2010;375(9725):1569-77
   PubMed Web of Science ®Google Scholar
• Gohil K, Bell JR, Ramachandran J, Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 1994;653(1-2):258-66
   PubMed Web of Science ®Google Scholar
• PRIALT (ziconotide intrathecal infusion). Prescribing information. Azur Pharma, Inc., Philadelphia, PA; 2010
   Google Scholar
• Staats PS, Yearwood T, Charapata SG, Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291:63-70
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Leong MS, A randomized, double-blind, placebocontrolled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406
   PubMed Web of Science ®Google Scholar
• Wallace MS, Charapata SG, Fisher R, Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006;9:75-86
   PubMed Web of Science ®Google Scholar
• Webster LR, Fisher R, Chrpata S, Wallace MS. Long-term intrathecal ziconotide for chronic pain: an open labeled study. J Pain Symptom Manage 2009;37(3):363-72
   PubMed Web of Science ®Google Scholar
• Wallace MS, Rauck R, Fisher R, Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008;106(2):628e637
   Web of Science ®Google Scholar
• Ellis DJ, Dissanayake S, McGuire D, Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation 2008;11(1):40-9
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009;6(2):344-51
   PubMed Web of Science ®Google Scholar
• Available from: http://www.chemicalbook.com/ChemicalProductProperty_EN_CB3190092.htm
   Google Scholar
• McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat 2007;3(1):69-85
   PubMedGoogle Scholar
• Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005;25:1084-94
   PubMed Web of Science ®Google Scholar
• Yaksh TL, De Kater A, Dean R, Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in dog. Neuromodulation 2012;15:508-19
   PubMed Web of Science ®Google Scholar
• Bowersox SS, Singh T, Nadasdi L, Cardiovascular effects of omega-conotoxins MVIIA and CVID in conscious rats: mechanisms of action. J Cardiovasc Pharmacol 1992;20:756-64
   PubMed Web of Science ®Google Scholar
• Battal B, Kocaoglu M, Bulanski N, Cerebrospinal Fluid Flow imaging by using phase-contrast MR technique. Br J Radiol 2011;84(1004):758-65
   PubMed Web of Science ®Google Scholar
• Bulat M, Klarica M. Recent insights into the hydrodynamics of the cerebrospinal fluid. Brain Res Rev 2011;65:99-112
   PubMedGoogle Scholar
• Henry-Feugeas MC, Idy-Peretti I, Baledent O, Origin of Subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging 2000;18(4):387-95
   PubMed Web of Science ®Google Scholar
• Friese S, Hamhaber U, Erb M, The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol 2004;39:120-30
   PubMed Web of Science ®Google Scholar
• Stockman HW. Effect of anatomic fine structure on the flow of cerebrospinal fluid in the spinal subarachnoid space. J Biochem Eng 2006;128:106-14
   Google Scholar
• Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry 1990;27:891-6
   PubMed Web of Science ®Google Scholar
• Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006;105:169-78
   PubMed Web of Science ®Google Scholar
• Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 2010;112:165-75
   PubMed Web of Science ®Google Scholar
• Flack SH, Anderson CM, Bernards CM. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011;112(2):460-4
   PubMed Web of Science ®Google Scholar
• Hejtmanek MR, Harvey TD, Bernards CM. Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion. Reg Anesth Pain Med 2011;36(1):7-11
   PubMed Web of Science ®Google Scholar
• Wermeling D, Drass M, Ellis D, Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003;43:624-36
   PubMed Web of Science ®Google Scholar
• Valentino K, Newcomb R, Gadbois T, A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993;90:7894-7
   PubMed Web of Science ®Google Scholar
• Smith H, Deer T. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 2009;5:521-34
   PubMedGoogle Scholar
• Brose WG, Gutlove DP, Luther RR, Use of intrathecal SNX- 111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997;13:256-9
   PubMed Web of Science ®Google Scholar
• Atanassoff PG, Hartmannsgruber MW, Thrasher J, Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000;25:274-8
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Burton AW, Intrathecal ziconotide for neuropathic pain: a review. Pain Pract 2009;9:327-37
   PubMed Web of Science ®Google Scholar
• Ridgeway B, Wallace M, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000;85:287-9
   PubMed Web of Science ®Google Scholar
• Lux EA. Successful treatment of a patient with trigeminal neuropathy using Ziconotide. Anesth Analg 2010;110:1195-7
   PubMed Web of Science ®Google Scholar
• Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 2010;26:635-44
   PubMed Web of Science ®Google Scholar
• Wang YX, Gao D, Pettus M, Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000;84:271-81
   PubMed Web of Science ®Google Scholar
• Wang YX, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000;6:1-20
   Google Scholar
• Deer T, Kim C, Bowman R, Intrathecal Ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician 2009;12:E291-6
   PubMed Web of Science ®Google Scholar
• Alicino I, Giglio M, Manca F, Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012;153:245-9
   PubMed Web of Science ®Google Scholar
• Dupoiron D, Bore F, Lefebvre-Kuntz D, Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician 2012;15:395-403
   PubMed Web of Science ®Google Scholar
• Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures containing 25 mug/mL ziconotide and 10 mg/mL or 20 mg/mL morphine sulfate during simulated intrathecal administration. Int J Pharm Compounding 2008;12:552-7
   Google Scholar
• Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005;8:257-63
   PubMed Web of Science ®Google Scholar
• Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):12-17
   PubMed Web of Science ®Google Scholar
• Shields D, Montenegro R. Chemical stability of ziconotide–clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):6-11
   PubMed Web of Science ®Google Scholar
• Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):1-5
   PubMed Web of Science ®Google Scholar
• Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compounding 2008;12:463-6
   PubMedGoogle Scholar
• Burton AW, Deer T, Wallace MS, Considerations and methodology for trialing Ziconotide. Pain Physician 2010;13:23-33
   PubMed Web of Science ®Google Scholar
• Mohammed SI, Eldabe S, Simpson KH, Bolus Intrathecal Injection of Ziconotide (Prialt) to evaluate the Option of Continuous Administration via an Implanted Intrathecal Drug Delivery System: a pilot study. Neuromodulation 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Maier C, Gockel HH, Gruhn K, Increased risk of suicide under intrathecal ziconotide treatment?-A warning. Pain 2011;152:235-7
   PubMed Web of Science ®Google Scholar
• Veixi IE, Hayek SM, Narouze S, Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011;12(10):1481-9
   PubMed Web of Science ®Google Scholar